Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting
Chad A Bousman, Philip Jaksa, Christos Pantelis
Pharmacogenetics and Genomics | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
OBJECTIVE: The aim of this study was to systematically assess commercial pharmacogenetic tests relevant to prescribing in psychiatry, with specific attention on CYP2D6 and CYP2C19 star allele coverage as well as compliance with consensus recommendations for pharmacogenetic test result reporting. MATERIALS AND METHODS: The CYP2D6 and CY2C19 star (*) allele contents of 20 pharmacogenetic test panels were compared and their test results reports were evaluated on the basis of consensus reporting recommendations published by The Centers for Disease Control and Prevention as well as the Clinical Pharmacogenetics Implementation Consortium. RESULTS: Most test panels included the major CYP2D6 (*2, *4..View full abstract
Awarded by National Health and Medical Research Council of Australia (NHMRC) Career Development Fellowship
Awarded by NHMRC Senior Principal Research Fellowship
C.B. was supported by a National Health and Medical Research Council of Australia (NHMRC) Career Development Fellowship (ID: 1127700). C.P. was supported by an NHMRC Senior Principal Research Fellowship (ID: 1105825). Over the last 5 years, C.P. has participated on Advisory Boards for Janssen-Cilag, Astra-Zeneca, Lundbeck, and Servier. He has received honoraria for talks presented at educational meetings organized by Astra-Zeneca, Janssen-Cilag, Eli-Lilly, Pfizer, Lundbeck, and Shire. For the remaining authors, there are no conflicts of interest.